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Introduction
 Sepsis continues to be a critical problem in regards to morbidity 
and mortality in the clinical setting. Ranked as a top cause of 
morbidity and mortality, sepsis can be the result of a number of 
pathologies and can greatly complicate the care of patients in and out 
of the hospital setting [1]. Despite advances in the treatment of sepsis, 
28 day in hospital mortality rates still range from 15 to 45% [2].
Epidemiology
 Inpatient expenses related to the treatment of sepsis infections are 
on the rise with annual costs estimated to be in excess of $20 billion 
[3]. This places sepsis as one of the most costly burdens on the health 
care system. Sepsis rates are on the rise (Table 1) [4]. The elderly 
population is at a greater risk for the development of sepsis and 
sepsis related complications. As a result this population makes up a 
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significant amount of the total number of sepsis patients [1]. Similar 
to the general population, the elderly also have experienced dramatic 
increases in sepsis hospitalizations as shown in table 2 [3]. A more 
recent study has shown that sepsis likely contributed between 30 and 
50% of mortality and had a large impact on healthcare costs in the 
US between 2010 and 2012 [4]. With the growing burden of sepsis on 
the healthcare system, there is a strong drive to develop more efficient 
mechanisms to detect and manage sepsis patients.
Mortality
 Mortality rates for sepsis in recent years have ranged from 18 to 
40%. The identification of the correct microbial strain and initiation of 
the proper antibiotic treatment could significantly affect the incidence 
of mortality in these patients. The highest incidences of mortality are 
associated with sepsis arising from nosocomial infections by 
organisms such as methicillin resistant and sensitive staphylococcus 
species, pseudomonas and both candida and non-candidal fungal 
infections. Polymicrobial infections are also associated with increased 
mortality rates [6].
 Biomarkers currently used in the identification and management 
of septic patients can provide insight into the response to therapy and 
prognosis. Although using biomarkers to rule in sepsis have not been 
identified with strong support, Lactate level measurements have been 
the greatest focus in recent years and have been shown to correlate 
well with mortality [7]. Lactate levels greater than 4.0 mmol/L have 
been shown to correlate with an increase in mortality. In addition, this 
correlation is even stronger if there is a coexistence of elevated lactate 
with observed hypotension [7]. Other sources have found correlations 
with 48 hour resolution of elevated lactate levels and sepsis prognosis 
[8].
Pathophysiology
 Sepsis and disease severity depend on various factors, ranging 
from the properties of the invading pathogen to the current immune 
status of the host [9]. Severe sepsis can develop following local 
infection and can stem from a number of sites including the abdomen, 
skin, soft tissue, urinary tract, lungs and is usually due to a primary 
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Abstract
 Every physician has been trained early in their careers on how 
to recognize and manage sepsis. Although sepsis has been one of 
the most researched ailments in medicine, it also remains one of the 
deadliest diseases in the face of recent advances. In this current 
article, we review the diagnostic and management criteria for 
Systemic Inflammatory Response Syndrome (SIRS), sepsis, 
severe sepsis, septic shock, and Multi Organ Dysfunction Syndrome 
(MODS). We then examine the implications of the “surviving sepsis” 
campaign as well as explore the philosophy of Early Goal Directed 
Therapy (EGDT) and its role in the modern day management of 
sepsis. In addition, we sought to highlight potential new biomarkers 
and current available therapies in sepsis.
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Sepsis: Epidemiology, Patho-
physiology, Classification, 
Biomarkers and Management
2000 Hospitalization 
Rate (per 10,000)
2008 Hospitalization 
Rate (per 10,000)
Sepsis as a Primary Dx 11.6 24
Sepsis as any Dx 22.1 37.7
Table 1: Sepsis Hospitalization Trends 2000-2008: Hospitalizations for sepsis 
have more than doubled from 2000 to 2008 demonstrating the increasing 
burden of sepsis on the US healthcare system [5].
Age Group 2003 Sepsis Hospitalization Rate (per 10,000)
2007 Sepsis Hospitalization 
Rate (per 10,000)
18-64 8.3 13
65-84 64.7 99.8
85+ 177.1 219.7
Table 2: Age specific Sepsis Hospitalization Rates in USA. Hospitalization 
rates increased dramatically in the 5 year span. The rates increased dramati-
cally in all age groups over the short 5 year period [3].
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bloodstream infection. The pathophysiology of sepsis can be 
initiated by the host response to a pathogen insult, particularly the 
outer membrane component of gram negative organisms such as 
Lipid A component of LPS (Lipopolysaccharide), also known as 
endotoxin or components of gram positive organisms such as 
lipoteichoic acid and peptidoglycan. Sepsis can also be triggered by 
viral, fungal, and parasitic components. The innate immune system 
is the first line of defense, which includes the monocytes and 
dendritic cells, which recognize various pathogens based on their 
pathogen recognition receptors. Through interaction of pathogenic 
components via signaling of Toll like Receptors on monocytes, 
the transcription factor NF-κB is activated and important pro-in-
flammatory cytokines are generated such as TNF-alpha and IL-1. 
These inflammatory cytokines then lead to production of mediators 
such as prostaglandins, leukotrienes, platelet-activating factor and 
phospholipase A2 which leads to increased vascular permeability 
and vasodilation. TNF-alpha and IL-1 also lead to the production of 
adhesion molecules such as E and P selectin that eventually leads 
to neutrophil recruitment and further endothelial injury through 
neutrophil components, particularly nitric oxide, which is a potent 
vasodilator which leads to septic shock [9]. Activated neutrophils also 
promote clearance of the bacteria. While beneficial, this process in 
turn can do more damage by contributing to more inflammation via 
respiratory burst, cytotoxicity, degranulation, vascular permeability 
and organ injury. Many sources of literature cite this massive trigger 
of inflammation as the “cytokine storm” [9].
 The adaptive immune system as well, plays an active role. The 
adaptive immune systems also attempt to attenuate the harmful effects 
of the proinflammatory state. For example, regulatory T cells produce 
various mediators such as IL-10 and TGF-beta to reduce 
inflammation. The complement cascade is also activated by 
microbial components leading to production of anaphylatoxins, 
chemotactic fragments and opsonins all of which lead to a 
proinflammatory state. Microbial components can also activate 
coagulation by activating factor XII of the coagulation cascade 
or indirectly through changing the endothelium function. The 
continual pro-inflammatory state also activates immunosuppressive 
mechanisms, leading to oscillations between hyper-inflammatory and 
immunosuppressive states during the clinical course of the disease. 
Some mechanisms propose that there is a shift towards a Th2 
(anti-inflammatory) response from a Th1 (pro-inflammatory) 
response [9]. With complement activation and coagulation cascade, 
micro-vascular blood flow may be compromised which will result 
in local ischemia, ultimately leading to global tissue hypoxia and 
insufficient oxygen delivery to meet oxygen demands of the 
body. This can lead to metabolic acidosis, hypotension, impaired 
myocardial contractility, multi-organ dysfunction syndrome and 
death [9].
Classification
 Sepsis is defined as a systemic illness where bacteria enter a 
normally sterile place in the body. The definition takes evidence of 
Systemic Inflammatory Response Syndrome (SIRS) and incorporates 
it with suspicion of a microbial origin. When this criteria includes 
acute organ dysfunction of at least one organ, this becomes severe 
sepsis. Further dysfunction accompanied with refractory hypotension 
or hypoperfusion, while fluid resuscitation is being attempted, 
classifies as septic shock. Finally, when organ dysfunction 
progresses to the point where the patient is unable to maintain 
homeostasis without intervention it’s called Multi-organ Dysfunction 
Syndrome (MODS). The creation of a staging system for sepsis has 
allowed for a goal driven therapy to improve out comes [6].
 Sepsis can be caused by a variety of pathogens. The classification 
of sepsis is typically described as either community-acquired or 
nosocomial in origin. They can be bacterial or fungal in etiology. In 
addition, infections are not mutually exclusive and polymicrobial 
infections can and do occur. Within the bacterial causes of severe 
sepsis, there is some controversy as to the primary causative agents. 
Different epidemiological studies have found both gram negative and 
gram positive organisms to be of the greatest cause. Historically the 
gram negative organisms were of the greatest prevalence, however; 
data has shown an increase in incidence of gram positive infections 
in recent years [6]. Of the gram positive organisms, Staphylococcus 
aureus and Streptococcus pneumoniae are the most common 
organisms found. Of the gram negative organisms, Escherichia coli, 
Klebsiella and Pseudomonas aeruginosa are found in the greatest 
numbers [10].
Risk factors
 There are many risk factors associated with sepsis and severe 
sepsis. Most of these factors relate to a patient’s ability to fight 
infection and the probability that acute organ failure develops in 
response to infection. In general, greater risk is associated with male 
gender, black race, age, and chronic health conditions. Age arguably 
might be the most important risk factor to consider. As patients age 
the incidence of severe sepsis increases disproportionately to the point 
where patients over the age of 65 years old account for more than 
50% of severe sepsis cases [11]. On the other end of the age spectrum 
neonates have a high incidence of severe sepsis and septic shock as 
well compared to the total population. Estimates attribute over 36% 
of all neonatal deaths to cases of neonatal sepsis worldwide [6]. 
Immature immune systems and early exposure to various microbial 
agents, including those stemming from maternal sources, have made 
neonatal sepsis potentially dangerous complication in this population 
with case fatality rates ranging from 7% to 25% [12]. Group B 
Streptococcal, and to a lesser degree E coli, infections appear to 
comprise the majority of cases with early onset. In later onset 
cases the causative agent is more likely to be coagulase negative 
Staphylococcus species and Staphylococcus aureus are the most 
common causative agents [12]. More than half of patients who present 
with severe sepsis have at least one chronic health condition 
concurrently. The most common chronic conditions are immune 
insufficiency (primary or secondary), cancer, chronic obstructive 
pulmonary disease, chronic renal disease, diabetes, and chronic 
liver disease. Situational risk factors include immunosuppressive 
Classification Parameter
Systemic  
Inflammatory  
Response Syndrome 
Core body temperature >38°C or <36°C HR ≥90 
bpm Respirations ≥20/min (or PaCO2 <32 mmHg) 
WBC ≥12,000/μl or≤4000/μl or >10% immature 
forms
Sepsis At least two SIRS criteria caused by known or 
suspected infection
Severe Sepsis Sepsis with acute organ dysfunction
Septic Shock Sepsis with persistent or refractory hypotension 
or tissue hypoperfusion despite adequate fluid 
resuscitation
Multi-Organ  
Dysfunction Syndrome
The presence of organ dysfunction in an acutely ill 
patient such that homeostasis cannot be maintained 
without intervention.
Table 3: Classification of Sepsis [6].
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drugs, malnutrition, prosthetic devices, and residence in long term 
care facilities. Of note, environmental factors such as cold weather 
coincide with greater occurrence of severe sepsis and increased 
mortality despite a similar severity of illness [11].
Diagnosis
 Sepsis is a disease that is classified by a wide variety of clinical 
presentations. It is important to mention the proper screening with 
a goal of early detection for better patient outcomes. Early detection 
is key for better patient outcomes which have been accomplished by 
the creation of screening tools. Patients who are already admitted for 
severe infections should be screened routinely for sepsis using the 
diagnostic criteria mentioned. It is imperative that these patients are 
diagnosed early to allow for the early implementation of therapy. 
There has been Sepsis screening tools developed for ICU care that 
assist in this process. It should be of the utmost importance to reduce 
the time to diagnosis in all patients.
 If there is clinical suspicion of an infection being the etiology of 
septic shock, there should be no delay in the prompt treatment with 
antimicrobials. Two or more blood cultures should be drawn once 
there is access to initiate treatment and more directed antimicrobial 
therapy for later on. Blood cultures should be drawn from peripheral 
sites, not from existing IV access and care should be taken that they 
are filled properly (>10ml of blood). If cultures prove to be positive 
from vascular access site, earlier than peripheral blood site this would 
suggest vascular access as the point of entry [6]. Ideally, Cultures of 
IV and catheters should also be taken with peripheral blood smears to 
help determine the source of infection [6].
 Gram stain is also a useful tool, most commonly for respiratory 
tract specimens, with positive cultures for lower respiratory tract 
infections. Simultaneously, tests such as Rapid influenza antigen should 
be used during proper seasons for additional information. As with 
most diagnoses a focused history is a crucial source of information. 
Use of the 1,3 Beta, D-glucan assay, mannan and anti mannan assay 
has proven useful for the early diagnosis of systemic fungal 
infections of which the usual culprit is invasive candidiasis [6]. 
However, it should be noted that false positives are possible with 
colonization alone, and more study is needed. Thorough analysis of 
specimens is required. It has been shown that a delay in treatment has 
adverse outcome for patients with sepsis. Therefore, it is imperative 
that clinical suspicion should be taken seriously as patients fall into 
parameters associated with sepsis. The clues involved can be put into 
5 different categories. Each of these categories should be considered 
when an infection is documented or suspected [6].
a. General variables
•	 Fever > 38 degrees C
•	 Hypothermia core temperature <36 degrees C
•	 Heart rate >90/min or more than two SD above the normal 
value range
•	 Tachypnea
•	 Altered mental status
•	 Significant edema or positive fluid balance > 20 mL/kg 
over/24hr
•	 Hyperglycemia plasma glucose >140 mg/dL or 7.7 mmol/L in 
the absence of diabetes
b. Inflammatory variables
•	 Leukocytosis WBC >12,000/microL
•	 leukopenia WBC count < 4000/uL
•	 Normal WBC count with greater than 10% immature forms 
(shift to left)
•	 Plasma C reactive protein more than 2 above normal value
•	 Plasma procalcitonin more than 2 above normal value
c. Hemodynamic
•	 Arterial hypotension Systolic Blood Pressure <90 mmHg, 
Mean Arterial Pressure <70 mmHg or a decrease in systolic 
blood pressure >40 mmHg in adults or less than two SD below 
normal for age.
•	 Organ dysfunction
•	 Arterial hypoxemia Pao2/Fio2 <300
•	 Acute Oliguria urine output < 0.5 mL/kg/hr for at least 2 hrs 
despite adequate fluid resuscitation
•	 Creatinine increase > 0.5 mg/dL or 44.2 micromol/L
•	 Coagulation abnormalities INR >1.5 or aPTT > 60s
•	 Thrombocytopenia platelet count < 100,000/microL
•	 Hyperbilirubinemia plasma total bilirubin > 4 mg/dL or 70 
micromol/L
d. Tissue perfusion variables
•	 Hyperlactatemia >1mmol/L
•	 Decreased capillary refill or mottling
 In some institutions these variables and also specifically the 
criteria as associated with the classification of sepsis are used in 
electronic medical records to trigger alerts and help with a timely 
diagnosis.
Biomarkers
 Biomarkers, although important in many other clinical diagnoses, 
have not been thoroughly studied and if used have the greatest efficacy 
in ruling out sepsis diagnoses. Further studies must be made into 
biomarkers for the early detection of sepsis as well as their use 
prognostically. Two biomarkers have been studied in adults for the 
early diagnosis of sepsis with a sensitivity and specificity greater than 
90% with a high positive predictive value. Group II phospholipase 2 
(PLA2-II) has been studied in brief with a high sensitivity and 
specificity for bacteremia in adults within 24 hours of admission. 
Although there was a high sensitivity and specificity for early 
diagnosis with CD64 it was unable to distinguish local from systemic 
infection and bacterial from viral infections [13]. It seems the CD64 
also know as Fc gamma RI which is displayed on neutrophils and 
monocytes, is more indicative of febrile infection.
 As stated before, currently biomarkers have the greatest use 
clinically as means to rule out sepsis. Both CD64 and PLA-II are 
research phase markers that may or may not show clinical application 
in the future [13]. Although there is data supporting the use of PCT to 
differentiate infectious from noninfectious forms of SIRS, it should be 
noted, as with most diagnoses, that biomarkers should only aid in the 
diagnosis. All of the aforementioned biomarkers were studied in only 
culture positive sepsis, further showing a weakness in the diagnostic 
value due to the possibility of culture negative sepsis [14].
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C-Reactive Protein
 C-Reactive Protein (CRP) is an acute phase reactant and 
biomarker used for tracking inflammation in response to infection 
and tissue injury. Although it is possible to aid in the diagnosis of 
severe sepsis, CRP is also elevated in the following conditions: late 
pregnancy, active inflammation, bacterial infections, viral infections, 
and elderly age. The specificity of CRP testing in severe sepsis and 
the use of CRP to track sepsis progression has never been proven. 
However, since severe sepsis is an inflammatory state, it follows that it 
should be used to create a picture in septic patients [15].
Procalcitonin
 Procalcitonin has been intensely studied in recent years and has 
had some positive feedback clinically. Studies have been done showing 
PCT to be of use in tracking the severity of sepsis in general (without 
any guidelines as of yet) with evidence of peak PCT levels immediately 
before death due to MODS [16-18]. Although it should be said that, 
most studies that showed this result were associated with severe sepsis 
secondary to burn injury. The most recent edition of Surviving Sepsis 
Campaign states that using PCT to differentiate acute inflammation 
from severe sepsis has not been demonstrated to be useful as of yet [6]. 
There is also a role for PCT to help guide antimicrobial therapy which 
has not been demonstrated to reduce mortality or morbidity but does 
offer less exposure of ICU patients to antimicrobials. Low PCT levels, 
along with other clinical factors, may aid in early discontinuation of 
antimicrobials [6,19]. Procalcitonin (PCT) level is currently the most 
reliable biomarkers due to its strong negative predictive value
Management
 The “Surviving Sepsis Campaign” is an international coalition of 
experts that developed categorical recommendations and suggestions 
on the resuscitation of patients experiencing septic shock. From this 
was created two “bundles” of care; one to be instituted within 3 hours 
and another within 6 hours.
 The first bundle is to be achieved within 3 hours of the 
identification of severe sepsis. At initiation of the protocol, 
baseline lactate levels should be obtained for later comparison 
and to get a sense of the patient’s current perfusion status. Blood 
cultures should also be drawn at this time for a more directed 
antimicrobial treatment plan, if possible, once resulted. To start 
treating the underlying cause broad spectrum antimicrobials will 
lay the framework for long term treatment. Finally, if the patient has 
a lactate greater than or equal to 4 mmol/L or hypotension at the 
time of presentation, they should be administered 30 ml/kg of 
crystalloid solution, where the time of presentation is defined as the 
time of triage in the emergency department or the earliest record of all 
the elements consistent with severe sepsis or septic shock [6].
 The second phase, to be completed within 6 hours, is to place a 
monitor and possibly adjust the previously started treatment. To 
start, fluid responsiveness should be assessed by methods noted 
in the hemodynamic resuscitation section. Patients, who cannot 
maintain a Mean Arterial Pressure (MAP) greater than 65 mmHg 
after an attempt at hemodynamic resuscitation, should be treated with 
vasopressors to prevent further hypotension. If hypotension persists 
(MAP less than 65 mm Hg) or if the baseline level of the drawn lactate 
was greater than 4 mmol/L volume status and tissue perfusion should 
be assessed again and the findings documented in accordance with 
table 1 diagnostic criteria. After this the lactate should be measured 
again if the initial lactate was elevated [6].
Antimicrobials
 Studies have shown that delay in the administration of 
intravenous antibiotics increased mortality. Antimicrobial therapy 
should be administered within the first hour of the recognition of 
severe sepsis or septic shock. This initial treatment should consist 
of one or more drugs that have activity against all likely pathogens 
(bacterial and/or viral) and at concentrations that have the ability to 
penetrate the tissues of the supposed point of entry or source of the 
sepsis. Anti fungals should only be used in those at risk of invasive 
fungal species. Treatment should also be directed based off of the 
setting in which the infection was developed and medical history [6].
 Reassessment of the patient after 6 hours should focus on 
monitoring and supporting organ function, treatment of 
complications, and careful de-escalation of care. This is in 
conjunction with the monitoring of lactate and other pertinent 
biomarkers to guide therapy. Empiric broad spectrum antibiotic 
therapy should not be continued for more than 3-5 days to prevent 
the emergence of resistant microbial species, minimize drug toxicity, 
and to reduce costs. Once cultures have returned their susceptibility 
profiles, targeted therapy should be initiated. The duration of therapy 
should normally not take more than 7-10 days barring a slow clinical 
response to therapy, immunodeficiency and infection with S. aureus, 
fungal infections and some viral infections [10].
Corticosteroid therapy
 The use of corticosteroids in the treatment of septic patients has 
proven to be quite controversial. The presence of glucocorticoids 
whether endogenous or exogenous is essential for control of the host 
inflammatory response. Almost unanimously, studies have shown 
high dose steroid regimen increases morbidity and mortality in 
patients with severe sepsis and in septic shock [20]. The question 
remaining is the efficacy of low dose treatment on sepsis outcomes. 
Low dose corticosteroid therapy is generally considered to be below 
300 mg/day [20]. Mortality rate has been shown to improve with 
the use of low dose corticosteroid therapy [21]. A number of studies 
showed 28 day mortality rates ranging from 10% to 30% below those 
of control groups [20]. In addition multiple studies have found that 
low dose corticosteroid treatment of septic patients significantly 
improved hemodynamic status through an increase in blood 
pressure and decreased duration of pressor usage [20,22]. Other 
studies have found no efficacy toward corticosteroid administration 
or found increased mortality [23,24]. Those observed to have the most 
benefit from therapy also were found to have adrenal insufficiency. 
The Surviving Sepsis campaign recommends use of corticosteroid 
therapy only in the presence of septic shock and only following a 
failure of blood pressure response to pressor and fluid therapies. The 
Surviving Sepsis campaign recommends hydrocortisone administra-
tion at 200 mg/day in these patients and gradual tapering off once 
pressor therapy is no longer needed to maintain adequate blood 
pressure [6].
Hyperglycemia management
 Septic shock has a tendency to raise blood glucose level. This 
effect is also present in various other illness and/or stressors and is 
collectively called “stress hyperglycemia”. It was thought initially that 
intensive management of glucose was the best route to take and the 
surviving sepsis guidelines in 2008 recommended that glucose be kept 
between 80-100 mg/dl [25]. However, it was noted by many medical 
institutions that this aggressive insulin management was leading to 
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marked hypoglycemia [26]. Researchers began to question whether 
the hypoglycemia induced by aggressive insulin therapy was more 
detrimental than maintaining the patient at a more normal 
physiologic glucose level. This is where the NICE-SUGAR study 
comes to our attention. This trial is the largest randomized control 
trial to date and looks at 2 populations of patients: those with 
aggressive insulin management and those with conventional 
management [27]. The investigators found that ICU patients in the 
aggressive insulin therapy group showed an increased in 90 day 
mortality in comparison to their conventional counterparts [27]. 
The investigators consequently recommended that keeping glucose 
levels below 180 mg/dl lowered mortality in comparison to tight 
management of the patient at a glucose level of 81 to 108 mg/dl [27]. 
Surviving sepsis was consequently updated and its 2012 publication 
recommended keeping patients below 180 mg/dl but no lower limit 
was set except for the avoidance of hypoglycemia and the avoidance of 
wide swings in glucose levels [6].
Hemodynamic resuscitation
 In the landmark 2001 paper by Rivers et al., the authors recognize 
several factors which are paramount to EGDT. These factors include 
physical findings, vital signs, central venous pressure, and urinary 
output [28]. Having these values are key to early detection and the 
start of rapid management to decrease mortality, but individually they 
do little to address and determine the level of global tissue hypoxia. 
A far better indicator of the patient’s hypoxia and condition is the 
observation and response of cardiac output to medical intervention 
[29]. By manipulating preload, arfterload, and contractility, the 
medical team can better perfuse vital organs and prevent the 
degradation of sepsis to septic shock and/or MODS [30]. The gold 
standard for such intervention revolves around fluid resuscitation and 
pressor therapy. Given the pharmacologic side effects of vasopressors, 
fluid therapy is usually considered first line. However, if a patient 
is not fluid responsive, then pressors are preferred as further fluid 
infusions will present its own set of issues such as edema, pleural 
effusions, high blood pressure, and acute renal failure [31]. Following 
surviving sepsis guidelines, Nor-epinephrine should be considered 
first line at a dose of 0.01-3 mcg/kg/min IV infusion [6]. Adjunctive 
therapy can include the use of 0.03 units/minute of Vasopressin to 
help improve perfusion. Epinephrine is considered a second line 
vasopressor but can also be added to Nor-epinephrine therapy, if 
Nor-epinephrine alone cannot maintain a MAP of 65 mm Hg [6].
 Fluid responsiveness is a large part of sepsis management and 
currently also one of the most researched topics in regards to reducing 
mortality. Patients are considered “fluid responsive” if fluid 
resuscitation alone improves the blood pressure [32]. After adequate 
replacement of intravascular volume, further infusion of fluid can 
adversely affect their hemodynamics. With fluid therapy used initially 
to improve tissue perfusion, it becomes imperative to identify whether 
patients  are fluid responsive or unresponsive. Those that are not respon-
sive to fluid therapy would then be candidates for pressor therapy. The 
desired effect of fluid therapy revolves around improving stroke volume 
and cardiac output. By increasing pre-load, there can be more filling of the 
ventricles and consequently greater contractility via the Frank-Star-
ling mechanism. Patients are defined as “Fluid-responsive” and 
“Non-responsive” depending on the degree of hemodynamic 
improvement in response to initial fluid bolus defined as an increase 
in stroke volume of 10-15% [32]. It has been proposed that heart-lung 
interactions can also be used to determine fluid responsiveness and 
in 2000 Michard, Pinsky, and Teboul published the caval index to be 
used on patients as a marker of fluid responsiveness [22]. The Caval 
Index is defined as;
Caval Index = (IVC-exp diameter - IVC insp diameter) / (IVC-exp 
diameter) * 100
 A normal IVC diameter is 1.5-2.5 cm and if there is a less than 
50% collapse of the IVC, this suggests fluid overload [33]. This type 
of patient would not benefit from fluid therapy and in fact can be 
harmed from hyperperfusion. By using ultrasonography to measure 
IVC diameter, we can determine a patient’s response to fluids without 
invasive methods such as swan ganz catheter or CVC.
 Another non-invasive tool used to assess fluid responsiveness is 
the passive leg raise test. Due to the large compliance of the venous 
system, the human body has a tendency to pool extra blood volume in 
the legs where the effects of gravity and compliance are felt the most. 
Physicians can utilize this physiological occurrence to guide their 
route of management. The technique is best done with the patient flat 
on their back with their feet propped up to 45 degrees. 30-90 seconds 
in this position is enough to replicate the effects of a 250cc bolus of 
fluids as blood is being returned to the effective circulation and 
causing an increase in preload [34]. There are many methods to 
measure the effects of this pseudo-bolus including stroke volume 
index via a cardiac output monitor or through a surrogate 
measurement such as pulse pressure via arterial line. Another way 
to measure this response to fluids would be to utilize the same 
ultrasonography techniques as used to measure the IVC and calculate 
the caval index as mentioned above.
 Each method has a set of advantages and disadvantages and it 
is up to the physician to determine which method is most likely to 
aid in their initial management of the patient. Invasive measures are 
best reserved for patients who already have a CVC and/or are being 
managed in the ICU under constant monitoring. Patients however 
who present acutely to the ED stand little benefit in going directly to 
invasive cardiac monitoring to assess fluid response. The major caveat 
here of course would be if the physician in unable to attain peripheral 
IV access and a CVC needs to be placed to gain circulatory access. 
However, in most cases, patients arriving to the ED would be better 
candidates for non-invasive measurements of fluid responsiveness via 
ultrasonography of the IVC before and after an initial trial fluid bolus 
or a passive leg raise test.
Recent Advances
EGDT in clinical trials
 Trials in recent years have looked to assess the effect of early goal 
directed therapies and standardized treatment bundles on sepsis 
outcomes. These various studies have yielded mixed results. The 
Surviving Sepsis Campaign treatment bundles were largely based off 
of the 2001 Rivers paper [28]. This study was one of many that found 
improved health outcomes with the implementation of a set protocol 
aimed at achieving a few key goals. These studies, demonstrating 
efficacy of treatment bundles and early goal directed therapies, 
all showed their value through observed reductions in mortality 
[24,35-37].
 Other studies, primarily the United States’ ProCESS, United 
Kingdom’s ProMISe and the Austrailasian ARISE studies, failed to 
find significant reductions in mortality following implementation 
of EGDT modalities and treatment bundles. These studies, 
following study protocols based on the 2001 Rivers paper, found 
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potential benefits of EGDT not directly associated with mortality. Not 
surprisingly these three studies found that following implementation 
of set protocols patients were more likely to receive therapies 
 included in the treatment bundles [38-40]. The ProCESS trial found 
an increase in length of hospital stay while the ProMISe trial found 
patients were more likely to receive higher levels care for sepsis 
[38,39]. The ARISE Trial interestingly found a decrease in the average 
time for sepsis patients spent in the Emergency Room offering 
another potential benefit [40]. The mix in results of these studies 
makes it difficult to definitively determine the benefits of EGDT and 
bundle set treatment modalities in sepsis. At this point it appears more 
research is needed to make definitive conclusions.
NICOM
 As sepsis therapy progresses, there is a push to continue to find 
non-invasive alternatives rather than relying on highly invasive 
methods of management such as PICC lines, CVC, and/or Swan Ganz 
catheter. Of specific interest to recent advances is the Non-invasive 
Cardiac Output Monitoring (NICOM) machine. The NICOM 
machine works by measuring the phase shift between superior 
thoracic leads and inferior abdominal leads. The machine elicits an 
alternating current in the upper thoracic leads where it then travels 
down through the vasculature and tissue to the lower leads, a process 
called “bioreactance” [41]. The phase shift is dependent largely on the 
volume of fluid in the large thoracic vasculature. By measuring the 
phase shift of the electrical impulses the machine calculates the stroke 
volume. The electrodes of the machine are also capable of monitoring 
heart rate. By taking the heart rate and stroke volume into the account, 
the machine provides real time feedback about cardiac output.
 There is still more research required to determine whether this 
method of monitoring is as reliable as inspiratory IVC diameter 
ultrasonography as well as the IVC diameter measurements before 
and after passive leg raise test. A few preliminary research studies have 
shown promise in the sensitivity of NICOM related to other currently 
accepted, yet invasive therapies [42-45]. Until further trials can prove 
the efficacy of this device in contrast to time tested gold standards like 
those mentioned previously, the NICOM machine will need to remain 
in a trial only phase before it can be rolled out to hospitals worldwide. 
There is certainly no harm in using it on patients as an added modality 
while still maintaining other methods to assess fluid response. This 
is exactly what is occurring at medical centers currently conducting 
clinical trials with the NICOM, but at this point the device should not 
be used as an end all for patient cardiac output monitoring.
 Yet, the machine holds much promise in the future management of 
sepsis patients, particularly in the realm of fluid management. While 
using Ultrasonography requires testing before and after a therapy is 
given (i.e., fluid bolus), NICOM can be left on the patient and give 
medical teams real time feedback on the patient’s cardiac output and 
fluid responsiveness. To the patient’s advantage particularly is the 
ability of this device to do all this in a non-invasive method and 
without cumbersome devices and modalities such as repeated 
ultrasounds and there is also reduced risk of nosocomial infections.
Conclusion
 Severe sepsis and septic shock while heavily researched; still impose 
a huge burden on patients and the healthcare system. While mortality 
rates have dropped in recent years, overall hospitalizations for sepsis 
have increased. Studies have been split on whether the establishment 
of protocols, like the EGDT series introduced in the Rivers 2001 
 
paper and those outlined by the Surviving Sepsis Campaign, should 
be credited with the observed drop in mortality. More research is 
needed to fully understand the efficacy of treatment bundles and 
identify the important components that should be included in them. 
We the authors feel the greatest potential in future management of 
sepsis patients is in the development of new biomarkers and improved 
methods in the assessment of fluid responsiveness. Additionally, 
there should be a continued push towards mastering non-invasive 
monitoring techniques and matching the sensitivity and accuracy of 
these techniques to those of current more invasive practices.
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